China’s Generic Sector To Consolidate As Uniformity Assessment Deadline Nears
This article was originally published in PharmAsia News
Executive Summary
Some of China’s generics companies will be eliminated as the government’s deadline to complete bioequivalence assessment of the initial 75 generics nears.